PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase

• Autori principali: Dahyun Park (Autore), Sungho Bea (Autore), Ji-Hwan Bae (Autore), Hyesung Lee (Autore), Young June Choe (Autore), Ju-Young Shin (Autore), Hoon Kim (Autore)
• Natura: Libro
• Pubblicazione: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Abstract Aims Protein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are novel lipid-lowering agents used in patients with cardiovascular disease. Despite reassuring safety data from pivotal trials, increasing evidence from real-world studies suggests that PCSK9i increase the risk of bacteri...